HEPATOCELLULAR CARCINOMA. RECENT ADVANCES IN DIAGNOSIS AND TREATMENT
https://doi.org/10.20514/2226-6704-2016-6-1-63-69
Abstract
In analytical review describes the pathogenic mechanisms of hepatocarcinogenesis and some risk factors of grow more serious progress of HCC. There modern classifications of HCC, aetiology, some of diagnostic methods in suspicion on HCC and different variants of treatment by means of medical drugs and nonmedical tactics are presented. The main risk factors for the development HCC — liver cirrhosis, man, the age of 50 year, HBV DNA > 104 copies/ml, positive HBeAg in blood serum, genotype С HBV, mutations in the area core promoter, increased activity ALT. The clinical example of patient with HCC and the outcome of liver cirrhosis are illustrated.
About the Authors
T. Y. ChernobrovkinaRussian Federation
Y. D. Yankovwskaya
Russian Federation
References
1. Gatcheva A.A., Storozhakov G.I., Lepkov S.V., Ettinger, A.O., Kosura S.D. The Influence of viral hepatitis B and C on the course and prognosis of hepatocellular carcinoma. Medical care. 2012; 2: 15-19.
2. Maev I.V., Dicheva D.T., Zhilyaev E.V., etc. Difficulties in the diagnosis of hepatocellular carcinoma. Consilium Med. 2010; 8: 63 -66.
3. Khazanov A.I. Hepatocellular carcinoma. In the book: Gastroenterology and Hepatology. M., 2011; 759-766.
4. Abelev G.I. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res. 1968; 28(7): 1344–1350.
5. Beasley R., Hwang L., Lin C. et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 1981; 221: 1129–1133.
6. Beasley R. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61: 1942–1956.
7. Bralet M.P. et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000; 32: 200-204.
8. Bergstrand C.G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Invest. 1956; 8(2): 174.
9. Degos F., Christidis C., Ganne-Carrie N. et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000; 47: 131–136.
10. Debruyne E.N., Delanghe J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha fetoprotein: new aspects and applications. Clin. Chim. Acta. 2008; 395(1–2): 19–26.
11. Fattovich G. et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97:2886-2895.
12. Farci P., Niro G. Clinical Features of Hepatitis D. Semin. Liver. Dis. 2012; 32: 228–236.
13. Fattovich G., Giustina V., Christensen E. et al. Influence of hepatitis Delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000; 46: 420–426.
14. Gorog D., Regoly-Merei J., Paku S. et al. Alphafetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J. Gastroenterol. 2005; 11: 5015–5018.
15. Kew M.C. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J. Viral. Hepat. 2012; 20: 345–349.
16. Liebman H.A. et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-1431.
17. Lopez J.B. Recent developments in the first detection of hepatocellular carcinoma. Clin. Biochem. Rev. 2005; 26: 65-79.
18. Montalto G., Cervello M., Giannitrapani L. et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 2002; 963: 13–20.
19. Malaguarnera G. et al. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 2010; 55: 2744-2755.
20. Marrero J.A. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37: 1114-1121.
21. McMahon B.J. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000; 32: 842-846.
22. Negro F., Papotti M., Taraglio S. et al. Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. J. Viral. Hepat. 1997; 4: 93–98.
23. Nakagawa T. et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int. J. Oncol. 1999; 14: 281-286.
24. Okuda H., Obata H., Motoike Y., Hisamitsu T. Clinicopathological features of hepatocellular carcinoma-comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology. 1984; 31: 64-68.
25. Sangiovanni A., Prati G., Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17‑year cohort study of 214 patients. Hepatology. 2006; 43: 1303–1310.
26. Shiratori Y. et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995; 22: 1027-1033.
27. Van Nieuwkerk C.M., Rauws E.A., Tytgat G.N., et al. Diagnosis and treatment of hepatocellular carcinoma: new approaches. New Tijdschr Geneeskd. 1996; 140(17): 922-926.
28. Yano M., Kumada H., Kage M. et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996; 23: 1334–1340.
29. Yoshima H. et al. Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid. Cancer Res. 1980; 40(11): 4276–4281.
30. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004; 130: 417-422.
Review
For citations:
Chernobrovkina T.Y., Yankovwskaya Y.D. HEPATOCELLULAR CARCINOMA. RECENT ADVANCES IN DIAGNOSIS AND TREATMENT. The Russian Archives of Internal Medicine. 2016;6(1):63-69. (In Russ.) https://doi.org/10.20514/2226-6704-2016-6-1-63-69